Updated:
Oruka Therapeutics
Oruka Therapeutics engineers semiannual biologics for chronic skin diseases — a publicly traded biotech commercializing half-life extension technology.
Oruka Therapeutics
Oruka Therapeutics formed through the combination of Paragon Therapeutics spinouts and ARCA biopharma, a Nasdaq-listed shell, closing the merger in August 2024. The company simultaneously raised $275 million in a private placement from a syndicate led by Fairmount, Venrock, and RTW Investments, which funded operations through anticipated clinical readouts for ORKA-001 and ORKA-002, two monoclonal antibody programs targeting psoriasis and atopic dermatitis via IL-23p19 and IL-17A inhibition respectively. Both programs leverage half-life extension technology designed to push subcutaneous dosing intervals to six months. Oruka's strategy focuses on biologics with validated mechanisms but underserved dosing convenience. The lead candidate ORKA-001 targets IL-23p19 — the same pathway as Johnson & Johnson's Tremfya, which generated $2.7 billion in 2023 revenue — but aims to replace quarterly injections with semiannual dosing. ORKA-002 targets IL-17A and treats psoriatic arthritis and ankylosing spondylitis. The company has not disclosed licensing terms with Paragon Therapeutics beyond standard upfront and milestone obligations tied to development progress. Its geographic footprint remains US-centric, with clinical trial sites in North America and potential EU expansion pending regulatory discussions. The company closed 2024 with cash runway into 2027, no revenue, and three full-time executives including CEO Lawrence Klein, a biotechnology entrepreneur known for prior roles at CRISPR Therapeutics. The reverse merger structure allowed Oruka to access public capital without a traditional IPO roadshow. Fairmount Funds Management took a board seat, joining representatives from Venrock and RTW. Oruka joined a vanguard of early-stage biotechs using reverse mergers following SEC rule changes in 2023 that streamlined the process. August 2024: Oruka Therapeutics debuted on Nasdaq under ticker ORKA, raising $275 million concurrently with the reverse merger close (per the firm, August 2024). Oruka operates as a publicly traded biotech company, not a traditional investment vehicle, with a fatal bet on long-acting biologic delivery. The structural differentiator is the half-life extension platform paired with a reverse merger financing strategy — a capital-efficient path that obviated an IPO while securing institutional backing from dedicated life sciences crossover funds. Governance sits within SEC-mandated public company structure, but board and syndicate concentration means Fairmount, Venrock, and RTW effectively own the development strategy through their combined stake.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What does Oruka Therapeutics actually develop?
Oruka develops monoclonal antibodies engineered for extended half-life to treat chronic skin diseases like psoriasis and atopic dermatitis. Its lead candidates, ORKA-001 and ORKA-002, target IL-23p19 and IL-17A respectively — both validated pathways with blockbuster precedent. The key twist is reducing dosing frequency from quarterly to once every six months, which the company argues could improve adherence and real-world outcomes.
How is Oruka Therapeutics funded?
Oruka went public via a reverse merger with ARCA biopharma in August 2024, simultaneously raising $275 million in a private placement led by Fairmount, Venrock, and RTW Investments. The company has no product revenue and expects this cash runway to fund operations into 2027 based on management guidance.
Why did Oruka use a reverse merger rather than a traditional IPO?
Oruka's reverse merger with ARCA biopharma allowed it to access public capital markets without the prolonged roadshow and pricing risk of a conventional IPO. This strategy has become more common among early-stage biotechs since SEC rule changes in 2023, and Oruka was able to price the concurrent PIPE efficiently with committed crossover life sciences investors.
Who are Oruka Therapeutics' largest shareholders?
The post-merger investor syndicate is led by Fairmount Funds Management, Venrock, and RTW Investments, each holding board representation alongside management. The exact ownership stakes are public filings, but the concentration of crossover life sciences investors suggests the syndicate collectively controls the strategic direction.
What is the clinical status of Oruka's pipeline?
ORKA-001, targeting IL-23p19 for psoriasis, and ORKA-002, targeting IL-17A for psoriatic arthritis and ankylosing spondylitis, are both in clinical development. Oruka has guided for data readouts within its current cash runway window through 2027. Neither candidate has completed Phase 3 or received regulatory approval as of early 2025.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: